Antihistamines, Amantadine and Evolution of the SARS-CoV-2 Infection

Study Overview
=================
Brief Summary
-----------------
The rates of symptomatic COVID19 infection, hospital admission among COVID19 cases and survival would be quantified in patiens chronically treated with antihistamines or amantadine, with the aim of determining the role of antihistamines and amantadine in the evolution of COVID19.

Detailed Description
-----------------
BACKGROUND: According to previous reports, all 84 eldery residents in nuersing homes in Yespes (Toledo, Spain), had a 100% of positive serology for COVID-19 in June 2020, but none died nor hospitalized after receiving early treatment with antihistamines. Other case reports have suggested a protective role of amantadine, since infected patients showed a very mild COVID19 infection. OBJECTIVES.Determine the role of antihistamines and amantadine in the evolution of COVID19. METHODS. Describe the rate of hospitalization, ICU and survival among COVID 19 cases having antihistamines and amantadine as chronic treatments. The rates would be stratified by age groups and compared with the same age groups of the population assigned to the public free Access Terrassa Health Consortium.

Official Title
-----------------
Evaluation of Treatments With Antihistamines and Amantadine in the Evolution of the SARS-CoV-2 Infection

Conditions
-----------------
COVID-19

Intervention / Treatment
-----------------
* Drug: Antihistamine
* Drug: Amantadine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients having chronic treatment with antihistamines or amantadine - Exclusion Criteria: None -
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with chronic treatment with antihistamines or amantadine<br>The % of patients having antihistamines or amantadine as chronic treatment that suffered COVID would be compared to the population of the Terrassa Health Consortium (THC) of the same age groups. | Drug: Antihistamine<br>* Observation of the rate of COVID19 infection, the rate of hospitalization and the rate of survival among patients previously treated with<br>* Other names: Antihistamine as crhonic treatment and COVID19 infection.;Drug: Amantadine<br>* Observation of the rate of COVID19 infection, the rate of hospitalization and the rate of survival among patients previously treated with amantadine<br>* Other names: Amantadine as chronic treatment and COVID19 infection.;|
| Other population of the THC<br>The % of patients of the Terrassa Health Consortium that suffered COVID19 infection of the same age groups. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hospital Admissions. | Rate of Hospitalization among COVID 19 infections | from march 2020. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Survival | Survival among COVID1 hospitalized cases. | from march 2020 | 
| Symptomatic infection | Patients suffering a symptomatic COVID19 infection within a determinate age group | from march 2020 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
antihistamines, amantadine, hospital admissions, survival